Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape

Roy Baynes, MD, PhD, currently serves as executive vice president and chief medical officer of Eikon Therapeutics, Inc. a privately-held biotechnology company. Prior to Eikon Therapeutics, Dr Baynes served as chief medical officer as well as senior vice president and head of global clinical development at Merck and Co, Inc, where he helped Merck become a leading oncology and global healthcare company. Dr Baynes also previously served as senior vice president of oncology, inflammation and respiratory therapeutics at Gilead Sciences, Inc, which was preceded by his service at Amgen, Inc as vice president of global clinical development and therapeutic area head for hematology/oncology. Before joining Amgen, Dr Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center, at Wayne State University. Dr Baynes has authored more than 150 publications and is a member or fellow of several international medical societies. He received his medical degree and doctorate in philosophy from the University of the Witwatersrand in South Africa and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital. Dr Baynes has received innumerable awards for his activities as a physician/scientist, and currently serves on the board of directors at Atara Biotherapeutics, Natera, Inc and Travere Therapeutics, Inc. 

Asthika Goonewardene, MBA, is a Managing Director at Truist Securities covering biotechnology companies with a focus on cell therapy, immuno-oncology, and antibody technology. Prior to joining the STRH Biotech team in 2019, Mr Goonewardene was a senior analyst with Bloomberg Intelligence, leading coverage of the global biotech sector. Before joining Bloomberg in 2011, Mr Goonewardene worked as a senior management consultant at Datamonitor.  He started his career as an analyst at OSI Pharmaceuticals in 2005, and first joined the sell-side in 2007, with the biotech team at Piper Jaffray in London. Mr Goonewardene holds a BS in Biotechnology and an MBA in Technology Management from Rochester Institute of Technology.